Gemma Gatta1, Laura Botta2, María José Sánchez3, Lesley Ann Anderson4, Daniela Pierannunzio5, Lisa Licitra6. 1. Evaluative Epidemiology, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venzian 1, Milan, Italy. Electronic address: gemma.gatta@istitutotumori.mi.it. 2. Evaluative Epidemiology, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venzian 1, Milan, Italy. Electronic address: laura.botta@istitutotumori.mi.it. 3. Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.G., Hospitales Universitarios de Granada/Universidad de Granada, 18080 Cuesta del Observatorio 4, Campus Universitario de Cartuja, Granada, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Melchor Fernández Almagro 3-5, 28029 Madrid, Spain. Electronic address: mariajose.sanchez.easp@juntadeandalucia.es. 4. Centre for Public Health, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast 2012, University Road Belfast, BT7 1NN Northern Ireland, UK. Electronic address: l.anderson@qub.ac.uk. 5. Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità,Viale Regina Elena 299, Rome, Italy. Electronic address: daniela.pierannunzio@iss.it. 6. Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venzian 1, Milan, Italy. Electronic address: lisa.licitra@istitutotumori.mi.it.
Abstract
BACKGROUND: Head and neck (H&N) cancers are a heterogeneous group of malignancies, affecting various sites, with different prognoses. The aims of this study are to analyse survival for patients with H&N cancers in relation to tumour location, to assess the change in survival between European countries, and to investigate whether survival improved over time. METHODS: We analysed about 250,000 H&N cancer cases from 86 cancer registries (CRs). Relative survival (RS) was estimated by sex, age, country and stage. We described survival time trends over 1999-2007, using the period approach. Model based survival estimates of relative excess risks (RERs) of death were also provided by country, after adjusting for sex, age and sub-site. RESULTS: Five-year RS was the poorest for hypopharynx (25%) and the highest for larynx (59%). Outcome was significantly better in female than in male patients. In Europe, age-standardised 5-year survival remained stable from 1999-2001 to 2005-2007 for laryngeal cancer, while it increased for all the other H&N cancers. Five-year age-standardised RS was low in Eastern countries, 47% for larynx and 28% for all the other H&N cancers combined, and high in Ireland and the United Kingdom (UK), and Northern Europe (62% and 46%). Adjustment for sub-site narrowed the difference between countries. Fifty-four percent of patients was diagnosed at advanced stage (regional or metastatic). Five-year RS for localised cases ranged between 42% (hypopharynx) and 74% (larynx). CONCLUSIONS: This study shows survival progresses during the study period. However, slightly more than half of patients were diagnosed with regional or metastatic disease at diagnosis. Early diagnosis and timely start of treatment are crucial to reduce the European gap to further improve H&N cancers outcome.
BACKGROUND: Head and neck (H&N) cancers are a heterogeneous group of malignancies, affecting various sites, with different prognoses. The aims of this study are to analyse survival for patients with H&N cancers in relation to tumour location, to assess the change in survival between European countries, and to investigate whether survival improved over time. METHODS: We analysed about 250,000 H&N cancer cases from 86 cancer registries (CRs). Relative survival (RS) was estimated by sex, age, country and stage. We described survival time trends over 1999-2007, using the period approach. Model based survival estimates of relative excess risks (RERs) of death were also provided by country, after adjusting for sex, age and sub-site. RESULTS: Five-year RS was the poorest for hypopharynx (25%) and the highest for larynx (59%). Outcome was significantly better in female than in male patients. In Europe, age-standardised 5-year survival remained stable from 1999-2001 to 2005-2007 for laryngeal cancer, while it increased for all the other H&N cancers. Five-year age-standardised RS was low in Eastern countries, 47% for larynx and 28% for all the other H&N cancers combined, and high in Ireland and the United Kingdom (UK), and Northern Europe (62% and 46%). Adjustment for sub-site narrowed the difference between countries. Fifty-four percent of patients was diagnosed at advanced stage (regional or metastatic). Five-year RS for localised cases ranged between 42% (hypopharynx) and 74% (larynx). CONCLUSIONS: This study shows survival progresses during the study period. However, slightly more than half of patients were diagnosed with regional or metastatic disease at diagnosis. Early diagnosis and timely start of treatment are crucial to reduce the European gap to further improve H&N cancers outcome.
Authors: M D Chirlaque; D Salmerón; J Galceran; A Ameijide; A Mateos; A Torrella; R Jiménez; N Larrañaga; R Marcos-Gragera; E Ardanaz; M Sant; P Minicozzi; C Navarro; M J Sánchez Journal: Clin Transl Oncol Date: 2017-07-17 Impact factor: 3.405
Authors: Luciana Lastrucci; Silvia Bertocci; Vittorio Bini; Simona Borghesi; Roberta De Majo; Andrea Rampini; Paola Pernici; Pietro Giovanni Gennari Journal: Radiol Med Date: 2017-01-09 Impact factor: 3.469
Authors: A Andreano; M Ansarin; D Alterio; R Bruschini; M G Valsecchi; A G Russo Journal: Acta Otorhinolaryngol Ital Date: 2018-02 Impact factor: 2.124